Bazarbachi, A.-H., Avet-Loiseau, H., Harousseau, J.-L., Bazarbachi, A., & Mohty, M. (2024). Precision medicine for multiple myeloma: The case for translocation (11;14). Cancer Treatment Reviews, 130, 102823. https://doi.org/10.1016/j.ctrv.2024.102823

Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Dhodapkar, M. V. (2024). Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 42(22), 2702–2712. https://doi.org/10.1200/jco.24.01008

Gordon, E. R., Chen, C., Adeuyan, O., Lapolla, B. A., Trager, M. H., Fahmy, L. M., Schreidah, C. M., Wetter, D. A., & Geskin, L. J. (2024). Retrospective analysis of multiple myeloma drug use in cutaneous toxicity of monoclonal gammopathy of undetermined significance. Journal of the American Academy of Dermatology, 91(1), 129–130. https://doi.org/10.1016/j.jaad.2024.02.050

Fu, J., Li, S., Ma, H., Yang, J., Pagnotti, G. M., Brown, L. M., Weiss, S. J., Mapara, M. Y., & Lentzsch, S. (2023). The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39769-8

Boutin, R., Lee, H.-F., Guan, T. L., Nguyen, T. T., Huang, X. F., Waller, D. D., Lu, J., Christine Chio, I. I., Michel, R. P., Sebag, M., & Tsantrizos, Y. S. (2023). Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer. Journal of Medicinal Chemistry, 66(23), 15776–15800. https://doi.org/10.1021/acs.jmedchem.3c01271

Najjar, M., McCarron, J., Cliff, E. R. S., Berger, K., Steensma, D. P., Al Hadidi, S., Chakraborty, R., Goodman, A., Anto, E., Greene, T., Sborov, D., & Mohyuddin, G. R. (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Network Open, 6(11), e2342195. https://doi.org/10.1001/jamanetworkopen.2023.42195

Sereda, Y., Alarid-Escudero, F., Bickell, N. A., Chang, S.-H., Colditz, G. A., Hur, C., Jalal, H., Myers, E. R., Layne, T. M., Wang, S.-Y., Yeh, J. M., Trikalinos, T. A., Sereda, Y., Alarid-Escudero, F., Bickell, N. A., Chang, S.-H., Colditz, G. A., Hur, C., … Jalal, H. (2023). Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program. JNCI Monographs, 2023(62), 219–230. https://doi.org/10.1093/jncimonographs/lgad021

Hentzen, S., Meirson, T., Koehn, K., Goodman, A., Chakraborty, R., Sborov, D., Rubinstein, S., & Mohyuddin, G. R. (2023). Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. European Journal of Haematology, 111(3), 491–498. Portico. https://doi.org/10.1111/ejh.14032

Chakraborty, R., Al Hadidi, S., Scheffer Cliff, E. R., & Mohyuddin, G. R. (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Advances, 7(15), 3932–3935. https://doi.org/10.1182/bloodadvances.2023009658

Brownlie, R. J., Kennedy, R., Wilson, E. B., Milanovic, M., Taylor, C. F., Wang, D., Davies, J. R., Owston, H., Adams, E. J., Stephenson, S., Caeser, R., Gewurz, B. E., Giannoudis, P. V., Scuoppo, C., McGonagle, D., Hodson, D. J., Tooze, R. M., Doody, G. M., Cook, G., … Klein, U. (2023). Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma. Blood Advances, 7(15), 3874–3890. https://doi.org/10.1182/bloodadvances.2022009044

Di Meo, F., Iyer, A., Akama, K., Cheng, R., Yu, C., Cesarano, A., Kurihara, N., Tenshin, H., Aljoufi, A., Marino, S., Soni, R. K., Roda, J., Sissons, J., Vu, L. P., Guzman, M., Huang, K., Laskowski, T., Broxmeyer, H. E., Roodman, D. G., & Perna, F. (2023). A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Reports Medicine, 4(7), 101110. https://doi.org/10.1016/j.xcrm.2023.101110

Li, S., Fu, J., Walker, C. J., Yang, J., Bhutani, D., Chakraborty, R., Mamillapalli, N., Mapara, M. Y., Landesman, Y., & Lentzsch, S. (2023). Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. Blood Advances, 7(12), 2926–2937. https://doi.org/10.1182/bloodadvances.2021006638

Chakraborty, R., Yi, J., Rybicki, L., Preussler, J., Deol, A., Loren, A., Savani, B., Jim, H. S. L., Cerny, J., Reynolds, J., Whitten, J., Wingard, J. R., McGuirk, J. P., Uberti, J., Khera, N., Stiff, P., Jaglowski, S. M., Hashmi, S., Holtan, S. G., … Majhail, N. S. (2023). Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Transplantation and Cellular Therapy, 29(6), 388.e1-388.e6. https://doi.org/10.1016/j.jtct.2023.02.011

Mohyuddin, G. R., Chakraborty, R., & Cliff, E. R. S. (2023). The promise and harms of screening for plasma cell dyscrasias. British Journal of Haematology, 200(6), 704–707. Portico. https://doi.org/10.1111/bjh.18634

Totiger, T. M., Chaudhry, S., Musi, E., Afaghani, J., Montoya, S., Owusu‐Ansah, F., Lee, S., Schwartz, G., Klimek, V., & Taylor, J. (2023). Protein biomarkers for response to XPO1 inhibition in haematologic malignancies. Journal of Cellular and Molecular Medicine, 27(4), 587–590. Portico. https://doi.org/10.1111/jcmm.17667

Cicero, K. I., Joffe, M., Patel, M., Chiuzan, C., Pentz, A., Ruff, P., Lentzsch, S., Leng, S., Jacobson, J. S., Rebbeck, T. R., & Neugut, A. I. (2022). Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men. Cancer Epidemiology, Biomarkers & Prevention, 31(12), 2192–2198. https://doi.org/10.1158/1055-9965.epi-22-0525

Landau, H. J., Orlando, E., Rodriguez, E. S., Applebaum, A., Mitchell, H.-R., Peled, J. U., Khan, N., Funnell, T., Chung, D., Scordo, M., Shah, G. L., LeStrange, N. J., Hambright, K. A., McElrath, C. M., Cazeau, N., Devlin, S. M., Perales, M.-A., van den Brink, M. R. M., & Giralt, S. A. (2022). Pilot Trial of Homebound Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 28(12), 832.e1-832.e7. https://doi.org/10.1016/j.jtct.2022.09.014

Javaugue, V., Rocha, A. B., Said, S. M., Santoriello, D., Hou, J., Dasari, S., Theis, J. D., Vrana, J. A., Batal, I., Larsen, C., Markowitz, G. S., D’Agati, V. D., McPhail, E. D., Leung, N., & Nasr, S. H. (2022). Clinicopathologic and proteomic characteristics of intratubular cytoplasmic AL amyloidosis. Kidney International, 102(4), 926–929. https://doi.org/10.1016/j.kint.2022.07.020

Choi, T., Ahn, W., Shin, D. W., Han, K., Kim, D., & Chun, S. (2022). Association between Kidney Function, Proteinuria and the Risk of Multiple Myeloma: A Population-Based Retrospective Cohort Study in South Korea. Cancer Research and Treatment, 54(3), 926–936. https://doi.org/10.4143/crt.2021.951

Nooka, A., Costa, L., Gasparetto, C., Richardson, P., Siegel, D., Chari, A., Lentzsch, S., Jagannath, S., & Mikhael, J. (2022). Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. Clinical Lymphoma Myeloma and Leukemia, 22(7), e526–e531. https://doi.org/10.1016/j.clml.2022.01.014

Kumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., Lentzsch, S., McCarthy, P. L., Jagannath, S., Yee, A. J., Little, R. F., & Raje, N. S. (2022). Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal, 12(6). https://doi.org/10.1038/s41408-022-00695-5

Chakraborty, R., Siddiqi, R., Willson, G., Gupta, S., Asghar, N., Husnain, M., Aljama, M. A., Behera, T. R., Anwer, F., Perrot, A., & Riaz, I. B. (2022). Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials. Cancer, 128(12), 2288–2297. Portico. https://doi.org/10.1002/cncr.34211

Efficace, F., Cottone, F., Sparano, F., Caocci, G., Vignetti, M., & Chakraborty, R. (2022). Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clinical Lymphoma Myeloma and Leukemia, 22(7), 442–459. https://doi.org/10.1016/j.clml.2022.01.009

Sidana, S., Kumar, S., Fraser, R., Estrada-Merly, N., Giralt, S., Agrawal, V., Anderson, L. D., Aljurf, M., Banerjee, R., Bashey, A., Battiwalla, M., Beitinjaneh, A., Chakraborty, R., Chhabra, S., Dhakal, B., Dholaria, B., Hashmi, S., Janakiram, M., Lee, C., … D’Souza, A. (2022). Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 28(2), 83.e1-83.e9. https://doi.org/10.1016/j.jtct.2021.10.022

Pasvolsky, O., Yeshurun, M., Fraser, R., Estrada-Merly, N., Rozovski, U., Shargian-Alon, L., Assal, A., Banerjee, R., Bumma, N., Gale, R. P., Hagen, P., Holmberg, L., Hossain, N. M., Lazarus, H. M., Lee, C., Mian, H., Miller, K. C., Nathan, S., Nagler, A., … D’Souza, A. (2021). Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation, 57(1), 31–37. https://doi.org/10.1038/s41409-021-01455-y

Said, S. M., Best Rocha, A., Valeri, A. M., Paueksakon, P., Dasari, S., Theis, J. D., Vrana, J. A., Obadina, M. O., Saghafi, D., Alexander, M. P., Sethi, S., Larsen, C. P., Joly, F., Dispenzieri, A., Bridoux, F., Sirac, C., Leung, N., Fogo, A. B., McPhail, E. D., & Nasr, S. H. (2022). The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis. Kidney International, 101(1), 152–163. https://doi.org/10.1016/j.kint.2021.10.019

Cunningham, I., Sánchez Sosa, S., & Hamele‐Bena, D. (2021). Single organ microenvironment and the common features of tumors of leukemia, lymphoma, and myeloma cells growing there: A literature review. European Journal of Haematology, 108(3), 169–177. Portico. https://doi.org/10.1111/ejh.13727